Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$302M |
| 2 |
Trade Desk
TTD
|
+$265M |
| 3 |
Illumina
ILMN
|
+$260M |
| 4 |
JMIA
Jumia Technologies
JMIA
|
+$260M |
| 5 |
AXON
Axon Enterprise
AXON
|
+$252M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verisk Analytics
VRSK
|
+$493M |
| 2 |
Baidu
BIDU
|
+$378M |
| 3 |
FRC
First Republic Bank
FRC
|
+$333M |
| 4 |
ICICI Bank
IBN
|
+$215M |
| 5 |
Stellantis
STLA
|
+$207M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 32.32% |
| 2 | Healthcare | 17.27% |
| 3 | Communication Services | 16.52% |
| 4 | Financials | 10.83% |
| 5 | Technology | 10.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGR
151
DELISTED
Avangrid, Inc.
AGR
| $24.8M | 0.03% |
490,110
+6,896
| +1% | +$350K |
|
152
Stratasys
SSYS
$706M
| $23.5M | 0.02% |
800,069
-5,048
| -0.6% | -$120K |
|
|
BNFT
153
DELISTED
Benefitfocus, Inc.
BNFT
| $23.4M | 0.02% |
860,147
-3,032
| -0.4% | -$102K |
|
154
Digimarc Corp
DMRC
$161M
| $22.8M | 0.02% |
513,108
-4,606
| -0.9% | -$210K |
|
|
FARO
155
DELISTED
Faro Technologies
FARO
| $20.7M | 0.02% |
394,639
+5,353
| +1% | +$271K |
|
156
Upwork
UPWK
$1.18B
| $20.6M | 0.02% |
+1,284,200
| New | +$22.1M |
|
157
Apple
AAPL
$4.46T
| $20.6M | 0.02% |
416,072
-141,316
| -25% | -$6.89M |
|
158
Cullen/Frost Bankers
CFR
$10.5B
| $20M | 0.02% |
213,431
+36,223
| +20% | +$3.54M |
|
159
Axogen
AXGN
$2.46B
| $19.3M | 0.02% |
975,000
-5,700
| -0.6% | -$122K |
|
160
Lindblad Expeditions
LIND
$2.17B
| $19.3M | 0.02% |
1,072,701
| – | – |
|
161
Pricesmart
PSMT
$6.08B
| $19.1M | 0.02% |
373,578
-825,389
| -69% | -$46.1M |
|
|
ZUO
162
DELISTED
Zuora, Inc.
ZUO
| $17.5M | 0.02% |
1,144,544
+68,412
| +6% | +$1.3M |
|
163
Ambarella
AMBA
$3.63B
| $17.4M | 0.02% |
394,204
-206
| -0.1% | -$9.23K |
|
|
ADAP
164
DELISTED
Adaptimmune Therapeutics
ADAP
| $16.7M | 0.02% |
4,143,840
+304,650
| +8% | +$1.24M |
|
165
M&T Bank
MTB
$36.2B
| $16.5M | 0.02% |
96,766
| – | – |
|
166
Eversource Energy
ES
$27.1B
| $16.3M | 0.02% |
214,588
-202,080
| -48% | -$14.8M |
|
167
Dolby
DLB
$5.59B
| $15.9M | 0.02% |
246,660
+952
| +0.4% | +$60.7K |
|
168
Xylem
XYL
$27.8B
| $15.9M | 0.02% |
189,933
+33,363
| +21% | +$2.66M |
|
169
Consolidated Edison
ED
$39.8B
| $15.7M | 0.02% |
179,488
-168,986
| -48% | -$14.6M |
|
|
BRFS
170
DELISTED
BRF SA
BRFS
| $15.4M | 0.02% |
2,022,530
-18,206,826
| -90% | -$132M |
|
171
Johnson & Johnson
JNJ
$613B
| $14.7M | 0.02% |
105,784
+2,638
| +3% | +$365K |
|
172
WEC Energy
WEC
$35.6B
| $14.6M | 0.02% |
175,290
-167,323
| -49% | -$13.4M |
|
173
Invesco Senior Income Trust
VVR
$457M
| $14.3M | 0.02% |
3,310,700
| – | – |
|
|
JT
174
DELISTED
Jianpu Technology Inc. American Depositary Shares, each representing twenty Class A Ordinary Shares
JT
| $14.3M | 0.02% |
476,523
-7,467
| -2% | -$276K |
|
175
Align Technology
ALGN
$12.4B
| $14M | 0.01% |
51,052
+42,375
| +488% | +$12.8M |
|
Similar funds
Baillie Gifford & Co's Q2 2019 Portfolio in Review
As of Q2 2019, Baillie Gifford & Co held 233 positions worth $94.3B, up 3.1% from $91.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Baillie Gifford & Co's Q2 2019 filing shows 6 new, 102 increased, 80 reduced and 7 closed positions. Its largest new stake was Jumia Technologies: 9,002,358 shares worth $238M. The largest sale was Verisk Analytics, an estimated $493M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Communication Services.
- Baillie Gifford & Co's largest Q2 2019 buy was Jumia Technologies: 9,002,358 shares worth $238M.
- Baillie Gifford & Co added most to Abiomed Inc in Q2 2019, an estimated $302M increase.
- Baillie Gifford & Co's biggest Q2 2019 reduction was Verisk Analytics, cutting an estimated $493M.
- Baillie Gifford & Co fully exited Vertex Pharmaceuticals in Q2 2019, selling an estimated $78.2M.
- Baillie Gifford & Co's ten largest holdings make up 45% of its $94.3B portfolio in Q2 2019.
- Baillie Gifford & Co opened 6 new positions and closed 7 in Q2 2019.
- Baillie Gifford & Co's portfolio value rose 3.1% quarter-over-quarter to $94.3B.
Based on Baillie Gifford & Co's 13F filing for Q2 2019, filed 8 Aug 2019.